How to Verify a Chinese Biotech Company
A Due Diligence Guide for International Partners

In 2025 alone, 16 biotech companies listed on the Hong Kong Stock Exchange under Chapter 18A, raising a combined HK$137.7 billion. The broader biotech sector raised HK$292.65 billion — a 751.7% year-on-year increase. For overseas investors, law firms, and corporate decision-makers, these numbers represent both opportunity and risk.

The opportunity is clear: China’s biotech sector is booming, and Hong Kong has become the second-largest biotech fundraising platform globally. But the risk is equally real. Biotech companies are inherently complex — pre-revenue, IP-intensive, and heavily dependent on regulatory approvals. When you add the cross-border dimension — language barriers, unfamiliar legal frameworks, and physical distance — the due diligence challenge becomes formidable.

This guide provides a practical framework for verifying Chinese biotech companies. Drawing on the latest market data and official information sources, we walk you through what to check, where to check it, and why each dimension matters.

1. Why Biotech Due Diligence Is Different

Standard corporate due diligence — verifying registration, checking financial statements, and reviewing legal records — is necessary but not sufficient for biotech companies. Here’s why:

First, biotech companies are often pre-revenue. Chapter 18A was explicitly designed to allow pre-profit, pre-revenue companies to access public markets. This means traditional financial metrics — profitability, revenue growth, cash flow — are not available as performance indicators. Instead, you must evaluate pipeline quality, clinical trial progress, and regulatory strategy.

Second, intellectual property is the core asset. For a biotech company, its patents, trademarks, and trade secrets are often more valuable than its physical assets. Verifying IP ownership — and ensuring the company has freedom to operate — is critical.

Third, regulatory compliance is existential. Biotech companies operate in a highly regulated environment. A single adverse regulatory decision — a clinical hold, a rejected application, a compliance violation — can destroy shareholder value.

Fourth, the corporate structure may be complex. As we’ve documented in previous articles, the trend toward mainland China incorporation (H-share structures) has accelerated. Among the 20 biotech companies that listed in 2024–2025, 14 were incorporated in mainland China — meaning that mainland-incorporated companies now account for more than one-third of all HKEX-listed biotech companies. This structural shift has significant implications for how information is accessed and verified.

2. Key Information Dimensions: What to Check

Based on our analysis of the HKEX biotech ecosystem and the due diligence requirements of international investors, we recommend checking the following eight dimensions:

2.1 Registration and Legal Status

This is the foundation of any due diligence exercise. You need to confirm that the company is properly incorporated, in good standing, and legally authorised to conduct its business. Key information includes:

• Company name and Unified Social Credit Code (USCC)
• Registered address and business scope
• Legal representative and incorporation date
• Registration status (active, dissolved, or deregistered)
• Share capital and ownership structure

2.2 Shareholder and Director Information

Understanding who owns and controls the company is essential for assessing conflicts of interest, governance quality, and ultimate beneficial ownership. You should verify:

• Major shareholders and their shareholding percentages
• Director identities and backgrounds
• Related-party relationships and potential conflicts
• Historical changes in ownership and management

2.3 Intellectual Property

For biotech companies, IP is the crown jewel. You need to verify:

• Patents owned or licensed (and their status: granted, pending, or expired)
• Trademarks and brand registrations
• Copyrights and trade secrets
• Licensing agreements and any restrictions on use
• Freedom-to-operate analysis

2.4 Financial Information

Even for pre-revenue companies, financial information provides critical insights into cash runway, burn rate, and financial discipline. You should review:

• Audited financial statements (where available)
• R&D expenditure and operating expenses
• Cash reserves and projected runway
• Debt obligations and contingent liabilities

2.5 Legal and Regulatory Risks

Biotech companies face significant legal and regulatory risks. You should check:

• Administrative penalties and regulatory actions
• Litigation history (ongoing or concluded)
• Regulatory approvals and clinical trial status
• Compliance with data protection and human genetic resources regulations

2.6 Clinical and Regulatory Status

For a pre-revenue biotech company, the clinical pipeline is its most important asset. You need to verify:

• Core Product status (as defined under Chapter 18A)
• Clinical trial phases and results
• Regulatory interactions and feedback
• Approval timelines and commercialisation plans

2.7 Corporate Governance

As we documented in our corporate governance analysis, governance practices vary significantly. Key indicators include:

• Board composition and independence (INEDs)
• Gender diversity (all 82 companies now meet the minimum female director requirement)
• CEO-chairman duality (62% of companies combine these roles)
• Executive team structure and experience

2.8 Employee Incentive Structures

Understanding how employees are incentivised provides insight into talent retention and alignment of interests. Pay attention to:

• Use of share option plans vs. employee shareholding platforms
• Vesting schedules and performance conditions
• Size of the employee incentive pool

3. Official Information Channels: Where to Check

China has a robust system of official corporate registries that provide public access to company information. The most important is the National Enterprise Credit Information Publicity System (NECIPS).

3.1 National Enterprise Credit Information Publicity System (NECIPS)

The NECIPS (www.gsxt.gov.cn) is China’s official corporate registry, operated by the State Administration for Market Regulation (SAMR)[reference:0][reference:1]. It allows anyone to verify a Chinese company’s registration status, Unified Social Credit Code, legal representative, registered address, business scope, and regulatory penalties — free of charge[reference:2].

The system supports queries by company name, Unified Social Credit Code, or registration number[reference:3]. Once you locate a company, you can generate an Official Enterprise Credit Information Report — a document that carries official watermarks and logos, providing authoritative verification of a company’s legal status[reference:4].

3.2 Other Official Sources

In addition to the NECIPS, several other official sources provide valuable information:

Source	Information Provided	Website
National Enterprise Credit Information Publicity System	Registration, shareholders, penalties, annual reports	gsxt.gov.cn[reference:6]
China Trademark Office	Trademark registrations and status	sbj.cnipa.gov.cn
China Patent Office (CNIPA)	Patent applications and grants	cnipa.gov.cn
China Court Online	Litigation records and judgments	court.gov.cn
Credit China	Credit information and失信名单	creditchina.gov.cn
HKEX Disclosure	Listed company filings and announcements	hkex.com.hk
Hong Kong Companies Registry	Hong Kong company registration and documents	icris.cr.gov.hk[reference:7]

3.3 The Limitations of Official Channels

While these official channels are authoritative, they have significant limitations for overseas users:

• Language barrier: All official systems are in Chinese. Navigating them requires literacy in Chinese legal and administrative terminology.
• Real-name authentication: Many systems require real-name registration with a Chinese ID card or mobile phone number — which overseas users typically do not have.
• Geographic restrictions: Some systems are only accessible from within China, or require local IP addresses.
• Fragmented information: Information is scattered across multiple systems — registration data in one place, IP in another, litigation in a third. Consolidating it requires significant effort.
• No English support: Official reports are issued only in Chinese, which may not be acceptable for overseas legal or regulatory purposes without translation and notarisation.

4. Typical Pain Points for Overseas Clients

Based on our experience working with international law firms, investment banks, and corporate clients, we have identified five recurring pain points in Chinese biotech due diligence:

Pain Point 1: Geographic Distance. Overseas clients are not physically present in China. They cannot personally visit government offices, attend court hearings, or conduct on-site inspections. Every piece of information must be obtained remotely — which is challenging when official systems are designed for domestic users.

Pain Point 2: Language Barrier. Most overseas professionals do not read Chinese. Official documents, court judgments, and regulatory filings are all in Chinese. Even if you can access the information, understanding it is another matter entirely.

Pain Point 3: Legal and Regulatory Complexity. China’s legal and regulatory framework is complex and evolving. Overseas clients are often unfamiliar with the nuances of PRC company law, securities regulation, and biotech-specific rules. This increases the risk of missing critical issues or misinterpreting what they find.

Pain Point 4: Real-Name Authentication. As noted above, many official systems require real-name registration with a Chinese ID or phone number. Overseas clients cannot complete this step, effectively locking them out of official information channels.

Pain Point 5: Fragmented and Inconsistent Information. Information about a single company may be scattered across multiple systems — registration data in one place, IP in another, litigation in a third. Consolidating it into a coherent picture requires significant time and expertise.

5. Lessons from the HKEX Biotech Market

The data from the 2024–2025 biotech listing cohort offers specific insights that inform due diligence practice.

Lesson 1: Incorporation jurisdiction matters. With 14 out of 20 recent listings incorporated in mainland China (H-share structures), overseas due diligence teams must be comfortable with PRC corporate records. Unlike Cayman Islands-incorporated companies, where the listed entity’s records are in English and governed by common law, H-share companies are governed by PRC law and maintain their records in Chinese.

Lesson 2: Governance varies widely. Our analysis of 82 HKEX-listed biotech companies found that 62% combine the CEO and chairman roles, and while all companies now have at least one female director, overall female representation is still only 22%. These governance features matter — they affect board independence, decision-making quality, and risk oversight.

Lesson 3: Employee incentives are structured differently. Among the 2024–2025 listing cohort, 14 out of 20 companies (all mainland-incorporated) used employee shareholding platforms rather than traditional share option plans. These structures have different economic and legal characteristics that due diligence teams need to understand.

Lesson 4: Post-IPO performance is highly variable. Of the 82 companies that listed between 2018 and 2025, only 27 were trading above their IPO price at the end of 2025. The average price change was +13.28%, but some companies gained over 700% while others lost significant value. This underscores the importance of rigorous pre-investment due diligence.

6. How ChinaBizInsight Can Help

ChinaBizInsight was founded to bridge the information gap between overseas clients and Chinese companies. Our tagline — “Know Your Chinese Partners” — reflects our core mission: to provide overseas businesses with the verified, reliable information they need to make informed decisions.

Here is how we can support your biotech due diligence:

Official Enterprise Credit Reports. We obtain official Enterprise Credit Information Reports directly from the National Enterprise Credit Information Publicity System. These reports carry official government watermarks and logos, providing authoritative verification of a company’s legal status, registration details, shareholder information, and regulatory history[reference:8]. Learn more about our official credit reports.

Customised Due Diligence Reports. For more complex requirements, we offer customised due diligence reports that go beyond the official registration data. Our Standard, Professional, and Financial-Tax reports integrate information from multiple authoritative sources — including litigation records, IP registrations, financial filings, and news monitoring — to provide a comprehensive picture of a company’s creditworthiness and risk profile. Explore our professional due diligence reports.

Director and Shareholder Background Checks. Our Executive Risk Report provides in-depth background checks on directors, shareholders, and senior executives — including their investment history, other directorships, and any regulatory or legal risks. Learn more about executive risk reports.

Hong Kong and Macau Company Information. For companies with Hong Kong or Macau subsidiaries — or for due diligence on Hong Kong-listed entities — we provide comprehensive company information from the Hong Kong Companies Registry and Macau counterparts. Access Hong Kong company information.

IP Verification. We can verify patent, trademark, and copyright registrations through official Chinese IP offices, providing you with certified copies of registration certificates and status reports. Learn about our IP verification services.

Document Notarisation and Apostille. For documents that need to be used in overseas legal or regulatory proceedings, we provide notarisation, legalisation, and apostille services — ensuring your Chinese company documents are recognised in your home jurisdiction. Learn about our authentication services.

7. Practical Scenarios

Here are four common scenarios where ChinaBizInsight’s services can support your due diligence:

Scenario 1: Pre-IPO Investment. Your fund is considering a pre-IPO investment in a Chinese biotech company that plans to list on HKEX under Chapter 18A. You need to verify the company’s legal status, ownership structure, IP portfolio, and regulatory compliance — before committing capital. ChinaBizInsight provides a comprehensive due diligence package covering all these dimensions.

Scenario 2: M&A Target Assessment. Your company is considering acquiring a Chinese biotech firm or its assets. You need to verify the target’s legal existence, IP ownership, and freedom from encumbrances. Our official credit reports and IP verification services provide the authoritative documentation you need.

Scenario 3: Supplier or Partner Verification. Your company is entering a commercial partnership with a Chinese biotech company — as a CRO partner, licensing partner, or distribution partner. You need to verify that the company is legitimate, creditworthy, and free of material risks. Our credit reports and risk assessments provide the confidence you need to proceed.

Scenario 4: Compliance and Regulatory Review. Your company already has a relationship with a Chinese biotech company and needs to periodically review its compliance status, regulatory standing, and any new legal risks. Our ongoing monitoring and periodic report updates keep you informed.

8. Conclusion

China’s biotech sector is one of the most dynamic innovation ecosystems in the world. Hong Kong’s Chapter 18A regime has created a world-class platform for these companies to access global capital. For overseas investors, law firms, and corporate partners, the opportunities are substantial.

But opportunity comes with responsibility — the responsibility to conduct thorough, rigorous due diligence. Biotech companies are complex. The regulatory environment is evolving. And the information you need is often locked behind language barriers, administrative procedures, and geographic distance.

ChinaBizInsight exists to remove those barriers. We provide overseas clients with verified, reliable, and actionable information about Chinese companies — so you can make confident, informed decisions.

Whether you are evaluating a pre-IPO investment, assessing an M&A target, verifying a potential partner, or conducting a compliance review, we are here to help. Contact us to discuss your due diligence needs.